Dr. Fred Beasley discusses how to improve experimental design and select the most appropriate animal models for your preclinical obesity research.
When conducting preclinical obesity research using animal models, researchers must consider many factors. They must select an appropriate model, define long-term dosing requirements and mitigate complications including subject-to-subject variability and regressions to and from an obese state arise.
In this webinar hosted by CrownBio, Dr. Fred Beasley presents tips and best practices for designing obesity studies, including how to choose the right animal model, best fit for study criteria and specific diet acceptance.
Key Learning Objectives
- How to select rodent models to fit study criteria and accept the dietary requirements
- Advantages and disadvantages of polygenic obesity models compared to monogenic models
- Tips for designing effective experiments for preclinical anti-obesity agent drug development
This webinar is most relevant to:
- Preclinical obesity researchers looking to optimize model selection and study design
- Drug developers who want to learn how to evaluate obesity models based on mode of action of their novel agents
Fred Beasley, PhD
Director of Scientific Engagement,
Cardiovascular and Metabolic Disease,
Dr Fred Beasley, Director of Scientific Engagement for the Cardiovascular and Metabolic Disease Division at Crown Bioscience, has extensive experience with the development of animal models, the design and execution of research projects and with client/operations communications.
Before he was with CrownBio, Fred served as in vivo biologist at the NASH/inflammation startup Jecure Therapeutics and as a Study Director at BTS Research, Southern California’s sole provider of preclinical NHP models.
Fred obtained his PhD in Microbiology and Immunology at the University of Western Ontario and completed postdoctoral training at UC San Diego and at Calibr/Scripps Research Institute. His research focus is the development of animal models to evaluate small molecule drugs against bacterial and parasitic pathogens, and he is an author on over 20 publications.